Five Astellas medicines added ¥143.9 billion in sales
44.9%XTANDI share of group revenue (site calculation)
¥480.3bnFive Strategic Brands sales
14.7%R&D ratio
What emerges
See the company through the numbers →In FY2025, the year ended March 2026, five Astellas Strategic Brands generated ¥480.3bn, up 43%. They are marketed medicines for conditions including cancers, an eye disease and menopausal symptoms. XTANDI remained the largest product at ¥960.8bn, about 44.9% of group revenue. Alongside selling medicines, Astellas conducts R&D internally and with pharmaceutical, biotech and academic partners. R&D expense was ¥314.8bn. The roughly ¥1 trillion of mid-2030s pipeline sales potential in its plan is an ambition, not current revenue or a guarantee of regulatory approval.